In the last three years, amyloid plaque-busting drugs Aduhelm (now discontinued) and Leqembi have been approved by the FDA for treating patients in the…
A recent study reported that sildenafil, sold under the brand name Viagra, and other medicines from the same group called phosphodiesterase type-5 inhibitors may…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
Alzheimer’s disease affects millions of people worldwide, and as the world’s population ages, that number is going up. But, the exact cause of Alzheimer’s…
Neurologists and Alzheimer’s research experts explain the side effect known as ARIA — or brain bleeds — associated with the use of anti-amyloid monoclonal antibody…
Biogen and Eisai’s monoclonal antibody drugs for Alzheimer’s — Aduhelm (now off the market) and Leqembi (fully approved by the FDA in 2023) —…
Biogen renounced ownership of their controversial anti-Alzheimer’s drug Aduhelm after years of dismal sales. The company is also halting an ongoing clinical trial set…
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…
Dementia can be isolating — for the person living with the disease, and for caregivers. It can also be generative. For a number of…
This article was made possible through sponsorship by Alzheon. Being Patient’s editorial team produced the interview with no review/approval process by the sponsor. Alzheimer’s…
UPDATE: 3 March 2024, 8:14 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Beta-amyloid plaques — sticky globs of protein — build up in the brains of people with Alzheimer’s disease. For decades, scientists have focused on…
It was 7:20 a.m. and Joel Braunstein, co-founder and CEO of C2N Diagnostics, was about to start his second meeting of the day. C2N…
Alzheimer’s disease affects one in every three people over the age of 85, and the scale of the epidemic is only worsening. While there…
This article is part of the series Diversity & Dementia, produced by Being Patient with support provided by Eisai. Some of the United States’s most widespread…